Curcumin inhibits aggregation of alpha-synuclein

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Amyloid-beta (Abeta) protein aggregation is central to Alzheimer's disease (AD) pathogenesis.
• Curcumin, a turmeric compound, binds Abeta and inhibits its aggregation.
• Similarities in amyloid formation kinetics between AD and Parkinson's disease (PD) suggest curcumin's potential in PD.

Purpose of the Study:

• To investigate the effect of curcumin on alpha-synuclein (AS) protein aggregation, a hallmark of PD.
• To determine if curcumin can inhibit AS oligomerization and aggregation in vitro and in cell models.

Main Methods:

• An in vitro model of AS aggregation was created using purified AS protein and Fe3+ (Fenton reaction).
• Curcumin's effect on AS aggregation and solubility was assessed in a dose-dependent manner.
• A cell-based assay using SH-SY5Y cells expressing mutant AS fused to DsRed2 was employed to quantify aggregation via high-throughput microscopy.

Main Results:

• Curcumin inhibited AS aggregation in a dose-dependent manner and increased protein solubility in vitro.
• In cell cultures, curcumin reduced mutant AS aggregation by over 32% within 48 hours.
• Automated image analysis provided an unbiased method for quantifying AS aggregation.

Conclusions:

• Curcumin effectively inhibits the oligomerization of alpha-synuclein into higher molecular weight aggregates.
• Curcumin demonstrates potential as a therapeutic compound for Parkinson's disease and associated conditions.
• Further exploration of curcumin for PD treatment is warranted based on these findings.